Neuropeptide αCGRP plays a key role in how exercise affects osteoarthritis progression in joints and bone

αCGRP deficiency did not change overall cartilage degradation scores but prevented cartilage extracellular matrix stiffening, altered subchondral bone remodeling, caused trabecular bone loss with intense exercise, and elevated proinflammatory serum markers—establishing αCGRP as a key mediator of joint and bone responses to mechanical stress during OA.

Controlled animal study using αCGRP knockout vs. wild-type mice with surgically induced OA (DMM model), subjected to moderate or intense treadmill exercise for 6 weeks. Assessed via histology, nanoCT imaging, atomic force microscopy, and multiplex serum immunoassays.

Understanding how neuropeptides like αCGRP regulate the joint response to exercise could lead to targeted therapies for osteoarthritis. If αCGRP signaling can be modulated, it may help protect bone and cartilage integrity during physical activity in people with OA.

This research adds to growing evidence that neuropeptides are not just pain signals—they actively regulate tissue health in joints and bone. αCGRP emerges as a dual regulator affecting both inflammation and structural remodeling, suggesting peptide-based interventions could complement exercise therapy for osteoarthritis.

Murine model only—results may not directly translate to human OA. Only male mice were studied. Exercise was treadmill-based and may not reflect all types of physical activity. The DMM model represents post-traumatic OA specifically, not age-related OA.